Skip to main content
NCBI home page
Clinical and Diagnostic Laboratory Immunology logoLink to Clinical and Diagnostic Laboratory Immunology
. 1995 Nov;2(6):685–688. doi: 10.1128/cdli.2.6.685-688.1995

Comparison of the vibriocidal antibody response in cholera due to Vibrio cholerae O139 Bengal with the response in cholera due to Vibrio cholerae O1.

F Qadri 1, G Mohi 1, J Hossain 1, T Azim 1, A M Khan 1, M A Salam 1, R B Sack 1, M J Albert 1, A M Svennerholm 1
PMCID: PMC170220  PMID: 8574829

Abstract

Vibrio cholerae serogroup O139, now considered to be the second organism capable of causing epidemic severe dehydrating cholera, contains a capsular polysaccharide which makes it difficult for it to be used in the conventional vibriocidal antibody assay optimized for V. cholerae O1. After modification of the procedure, which involved the use of specific bacterial strains, a lower bacterial inoculum, and increased amounts of complement, the vibriocidal antibody responses to V. cholerae O139 were measured in acute- and convalescent-phase sera from 33 V. cholerae O139-infected and 18 V. cholerae O1-infected patients and in single serum samples from 20 healthy control subjects. The responses in these individuals to V. cholerae O1 strains were also determined. Significant elevations in the homologous antibody response were found only in the convalescent-phase sera from both groups of patients with cholera. These findings may explain the basis for the lack of heterologous protection between the two serogroups of V. cholerae. Healthy controls had higher background levels of vibriocidal antibody to V. cholerae O1 than to V. cholerae O139.

Full Text

The Full Text of this article is available as a PDF (202.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Albert M. J., Alam K., Ansaruzzaman M., Qadri F., Sack R. B. Lack of cross-protection against diarrhea due to Vibrio cholerae O139 (Bengal strain) after oral immunization of rabbits with V. cholerae O1 vaccine strain CVD103-HgR. J Infect Dis. 1994 Jan;169(1):230–231. doi: 10.1093/infdis/169.1.230. [DOI] [PubMed] [Google Scholar]
  2. Albert M. J., Alam K., Rahman A. S., Huda S., Sack R. B. Lack of cross-protection against diarrhea due to Vibrio cholerae O1 after oral immunization of rabbits with V. cholerae O139 Bengal. J Infect Dis. 1994 Mar;169(3):709–710. doi: 10.1093/infdis/169.3.709. [DOI] [PubMed] [Google Scholar]
  3. Albert M. J., Siddique A. K., Islam M. S., Faruque A. S., Ansaruzzaman M., Faruque S. M., Sack R. B. Large outbreak of clinical cholera due to Vibrio cholerae non-O1 in Bangladesh. Lancet. 1993 Mar 13;341(8846):704–704. doi: 10.1016/0140-6736(93)90481-u. [DOI] [PubMed] [Google Scholar]
  4. Albert M. J. Vibrio cholerae O139 Bengal. J Clin Microbiol. 1994 Oct;32(10):2345–2349. doi: 10.1128/jcm.32.10.2345-2349.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Comstock L. E., Maneval D., Jr, Panigrahi P., Joseph A., Levine M. M., Kaper J. B., Morris J. G., Jr, Johnson J. A. The capsule and O antigen in Vibrio cholerae O139 Bengal are associated with a genetic region not present in Vibrio cholerae O1. Infect Immun. 1995 Jan;63(1):317–323. doi: 10.1128/iai.63.1.317-323.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Glass R. I., Svennerholm A. M., Khan M. R., Huda S., Huq M. I., Holmgren J. Seroepidemiological studies of El Tor cholera in Bangladesh: association of serum antibody levels with protection. J Infect Dis. 1985 Feb;151(2):236–242. doi: 10.1093/infdis/151.2.236. [DOI] [PubMed] [Google Scholar]
  7. Goldman R. C., Joiner K., Leive L. Serum-resistant mutants of Escherichia coli O111 contain increased lipopolysaccharide, lack an O antigen-containing capsule, and cover more of their lipid A core with O antigen. J Bacteriol. 1984 Sep;159(3):877–882. doi: 10.1128/jb.159.3.877-882.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Hall R. H., Khambaty F. M., Kothary M. H., Keasler S. P., Tall B. D. Vibrio cholerae non-O1 serogroup associated with cholera gravis genetically and physiologically resembles O1 E1 Tor cholera strains. Infect Immun. 1994 Sep;62(9):3859–3863. doi: 10.1128/iai.62.9.3859-3863.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Hisatsune K., Kondo S., Isshiki Y., Iguchi T., Kawamata Y., Shimada T. O-antigenic lipopolysaccharide of Vibrio cholerae O139 Bengal, a new epidemic strain for recent cholera in the Indian subcontinent. Biochem Biophys Res Commun. 1993 Nov 15;196(3):1309–1315. doi: 10.1006/bbrc.1993.2395. [DOI] [PubMed] [Google Scholar]
  10. Jertborn M., Svennerholm A. M., Holmgren J. Saliva, breast milk, and serum antibody responses as indirect measures of intestinal immunity after oral cholera vaccination or natural disease. J Clin Microbiol. 1986 Aug;24(2):203–209. doi: 10.1128/jcm.24.2.203-209.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Johnson J. A., Salles C. A., Panigrahi P., Albert M. J., Wright A. C., Johnson R. J., Morris J. G., Jr Vibrio cholerae O139 synonym bengal is closely related to Vibrio cholerae El Tor but has important differences. Infect Immun. 1994 May;62(5):2108–2110. doi: 10.1128/iai.62.5.2108-2110.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Levine M. M., Kaper J. B., Herrington D., Ketley J., Losonsky G., Tacket C. O., Tall B., Cryz S. Safety, immunogenicity, and efficacy of recombinant live oral cholera vaccines, CVD 103 and CVD 103-HgR. Lancet. 1988 Aug 27;2(8609):467–470. doi: 10.1016/s0140-6736(88)90120-1. [DOI] [PubMed] [Google Scholar]
  13. Morris J. G., Jr, Losonsky G. E., Johnson J. A., Tacket C. O., Nataro J. P., Panigrahi P., Levin M. M. Clinical and immunologic characteristics of Vibrio cholerae O139 Bengal infection in North American volunteers. J Infect Dis. 1995 Apr;171(4):903–908. doi: 10.1093/infdis/171.4.903. [DOI] [PubMed] [Google Scholar]
  14. Qadri F., Azim T., Chowdhury A., Hossain J., Sack R. B., Albert M. J. Production, characterization, and application of monoclonal antibodies to Vibrio cholerae O139 synonym Bengal. Clin Diagn Lab Immunol. 1994 Jan;1(1):51–54. doi: 10.1128/cdli.1.1.51-54.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Svennerholm A. M., Jertborn M., Gothefors L., Karim A. M., Sack D. A., Holmgren J. Mucosal antitoxic and antibacterial immunity after cholera disease and after immunization with a combined B subunit-whole cell vaccine. J Infect Dis. 1984 Jun;149(6):884–893. doi: 10.1093/infdis/149.6.884. [DOI] [PubMed] [Google Scholar]
  16. Swerdlow D. L., Ries A. A. Vibrio cholerae non-O1--the eighth pandemic? Lancet. 1993 Aug 14;342(8868):382–383. doi: 10.1016/0140-6736(93)92806-5. [DOI] [PubMed] [Google Scholar]
  17. Waldor M. K., Colwell R., Mekalanos J. J. The Vibrio cholerae O139 serogroup antigen includes an O-antigen capsule and lipopolysaccharide virulence determinants. Proc Natl Acad Sci U S A. 1994 Nov 22;91(24):11388–11392. doi: 10.1073/pnas.91.24.11388. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Weintraub A., Widmalm G., Jansson P. E., Jansson M., Hultenby K., Albert M. J. Vibrio cholerae O139 Bengal possesses a capsular polysaccharide which may confer increased virulence. Microb Pathog. 1994 Mar;16(3):235–241. doi: 10.1006/mpat.1994.1024. [DOI] [PubMed] [Google Scholar]

Articles from Clinical and Diagnostic Laboratory Immunology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES